Update from 2008 ASCO Meeting in Chicago
Some thoughts from Kate Murphy. . .
We’ve known for a long time that cancer isn’t one disease and that colorectal cancer isn’t one disease either. Too often the only way to know if a treatment would work for a patient was to give it to them and wait. Meanwhile, the patients struggled through side effects, not knowing if the treatment was going to really help or not. And — even worse — lost valuable time that might have been spent with a more effective therapy.
Probably the most important theme at ASCO this year for colorectal cancer is that we now have real tools to target the right therapy to the right patient.
On Sunday at the Plenary Session — the big meeting for everyone where the most important cancer breakthroughs are discussed — Dr. Eric Van Cutsem presented the results of the Crystal trial with a special focus on KRAS. Crystal randomized patients who had not be treated for metastatic colorectal cancer before to FOLFIRI or FOLFIRI plus Erbitux® (cetuximab). Read the rest of this entry »